Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 20

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 2
Chunk 20
---
ander Therapeutics, Inc. $82,275 and $82,275 of revenue recognized during
the nine months ended June 30, 2025 and 2024 were recognized pursuant to licenses granted to Oncology Pharma, Inc.

Operating
Expenses

Operating
Expense were $392,680 for the nine months ended June 30, 2025 and $ 509,013 for the same period ended 2024. The primarily operating expense
for 2025 consists of $ 267,816 of Consulting & Professional expenses and $67,500 in rent. In the same period in previous year Consulting
and Professional fees expenditure were $295,839 During the period ended 2024 research and development expenses amounted to $120,161 constituting
the second largest expense recognized during that period.

  23  

Other
Income

For
the three months ended June 30 2025, the Company reported a net other expense of $(126,526) whereas in the same period ended 2024 the
Company reported the net other expense of $(22,154). Net other expense for the quarter ended 2025 was primarily driven by the recognition
of a Derivative Loss of $(89,259). For the quarter ended June 30, 2025 the Company also recognized higher interest and amortization expenses
as compared to the quarter ended 2024.

For
the nine months ended June 30 2025, the Company reported a net other expense of $(468,548) whereas in the same period ended 2024 the
Company reported the net other expense of $(65,688). Net other expense was primarily driven by the recognition of a Derivative Expense
in of $(376,312) in 2025. For the period ended June 30, 2025 the Company also recognized higher interest and amortization expenses as
compared to the period ended 2024.

Net
Loss

The
Company recognized an Operating Loss of $215,486 during the nine months ended June 30, 2025 whereas the Company recognized an Operating
Loss of $331,819 for the same period ended 2024. The reduction in operating loss is primarily attributable to a reduction in all expense
categories other than General and Administrative expenses and rent incurred during the period ended 2025 as compared to the period ended
in 2025.

Net
Loss is $ 702,033 for the nine months ended June 30, 2025 as opposed to a Net Loss of